COMPASS Pathways plc (CMPS)
| Market Cap | 1.27B +282.2% |
| Revenue (ttm) | n/a |
| Net Income | -287.86M |
| EPS | -3.08 |
| Shares Out | 134.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,809,684 |
| Open | 9.72 |
| Previous Close | 9.76 |
| Day's Range | 9.14 - 9.80 |
| 52-Week Range | 2.25 - 10.21 |
| Beta | 2.40 |
| Analysts | Strong Buy |
| Price Target | 24.56 (+161.56%) |
| Earnings Date | May 13, 2026 |
About CMPS
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in L... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price target is $24.56, which is an increase of 161.56% from the latest price.
News
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum
Psychedelic drug development is accelerating due to regulatory support, with multiple late-stage trials underway and companies preparing for commercial launches. Market differentiation will depend on efficacy, duration, and ease of use, while payer adoption and scalable infrastructure are key to broad access.
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced toda...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the ...
COMPASS Pathways Transcript: 25th Annual Needham Virtual Healthcare Conference
COMP360's phase III data show rapid, durable efficacy in treatment-resistant depression, with regulatory submission underway and commercial launch targeted for year-end. Leveraging existing SPRAVATO infrastructure and new reimbursement codes, the company aims for broad access, focusing on high-volume sites and streamlined provider training.
Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
COMPASS Pathways Transcript: Stifel 2026 Virtual CNS Forum
COMP360 is advancing toward a rolling NDA submission with final data expected early Q3 and a potential launch by year-end, targeting treatment-resistant depression. Commercial efforts focus on access, site readiness, and reimbursement, while early PTSD data is promising and financial runway extends into 2028.
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
COMPASS Pathways Transcript: TD Cowen 46th Annual Health Care Conference
Phase III trials demonstrated rapid, durable, and clinically meaningful improvements in TRD patients, with a strong safety profile and consistent results across studies. Regulatory engagement is robust, with accelerated timelines and future data releases planned.
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod...
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Announces Pricing of $150 Million Public Offering
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of i...
Compass Pathways Launches Proposed $150.0 Million Public Offering
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod...
COMPASS Pathways Transcript: Study update
Phase III trials of COMP360 in treatment-resistant depression showed rapid, durable, and clinically meaningful efficacy, with significant symptom reduction sustained up to 26 weeks after one or two doses. The safety profile was favorable, and regulatory submission is underway.
Compass Pathways' depression treatment meets main goal in late‑stage study
Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.